Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALY-002 in Healthy Volunteers, Celiac Disease, and Eosinophilic Esophagitis
NCT04593251Phase 1Completed
- Sponsor
- Calypso Biotech
- Start
- Sep 2020
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial in celiac disease and eosinophilic esophagitis (EoE) comparing CALY-002 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events. Started Sep 2020; status: completed.
02
Drugs
caly-002
03
Conditions
celiac diseaseeosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04593251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593251.